
CorMedix (CRMD) Stock Forecast & Price Target
CorMedix (CRMD) Analyst Ratings
Bulls say
Cormedix Inc. is projecting strong financial performance, with fourth-quarter net revenue expected between $115 million and $135 million, and full-year pro forma adjusted EBITDA guidance increased to $220 million to $240 million. The company has raised its full-year 2025 pro forma net revenue guidance to a range of $390 million to $410 million, largely due to the robust adoption of its product, DefenCath, and early contributions from the Melinta portfolio. Additionally, positive metrics from recent quarters, including a net revenue of $104.3 million in Q3 2025 driven by higher utilization of DefenCath among outpatient dialysis customers, reinforce the positive commercial execution narrative.
Bears say
Cormedix Inc faces a challenging outlook primarily due to the anticipated significant price drop of its product DefenCath following the second phase of the Transitional Drug Add-on Payment Adjustment (TDAPA) in July 2026. The company also risks underperforming in projected catheter lock solution sales, particularly as it competes against established generics like Heparin, which may impede revenue generation. Despite potential opportunities through its product Niyadas, the overshadowing uncertainties surrounding TDAPA pricing and competitive dynamics create a negative sentiment regarding the company's financial future.
This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.
CorMedix (CRMD) Analyst Forecast & Price Prediction
Start investing in CorMedix (CRMD)
Order type
Buy in
Order amount
Est. shares
0 shares